Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.63 |
| ▸ | NPC1 | O15118 | 6/20 | 0.59 |
| ▸ | RAB9A | P51151 | 6/20 | 0.59 |
| ▸ | BACE1 | P56817 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.56 |
| ▸ | RELA | Q04206 | 1/20 | 0.56 |
| ▸ | GCK | P35557 | 5/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7128392 | 0.86 | SMN1; SMN2 (0.65) | HPGDSMN1; SMN2MEN1KMT2AL3MBTL1 | |
| SCHEMBL5713422 | 0.85 | POLB (0.68) | SMN1; SMN2MEN1KMT2ANPC1RAB9A | |
| SCHEMBL5713417 | 0.79 | MITF (0.50) | SMN1; SMN2MEN1KMT2ANPC1RAB9A | |
| SCHEMBL5713383 | 0.79 | NPC1 (0.65) | HPGDSMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL27771294 | 0.79 | KMT2A (0.77) | HPGDSMN1; SMN2MEN1KMT2AL3MBTL1 | |
| SCHEMBL5713407 | 0.78 | NPC1 (0.64) | SMN1; SMN2MEN1KMT2ANPC1RAB9A | |
| SCHEMBL27930260 | 0.75 | L3MBTL1 (0.63) | SMN1; SMN2MEN1KMT2AL3MBTL1NPC1 | |
| SCHEMBL28493356 | 0.72 | KMT2A (0.71) | SMN1; SMN2MEN1KMT2ANPC1RAB9A | |
| SCHEMBL5713408 | 0.71 | KMT2A (0.56) | HPGDSMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL7128929 | 0.70 | RAB9A (0.67) | SMN1; SMN2MEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0973727-B8 | ACTIVATED IODODERIVATIVES FOR THE TREATMENT OF CANCER AND AIDS | ISOTECHNIKA INTERNATIONAL INC (BB) | 2006-01-18 | — | — | EP | disclosed |
| EP-0973727-B1 | ACTIVATED IODODERIVATIVES FOR THE TREATMENT OF CANCER AND AIDS | ISOTECHNIKA INC (CA) | 2005-10-26 | — | — | EP | disclosed |
| US-6780995-B2 | VIRICIDES; ANTICANCER AGENTS | ISOTECHNIKA INC. (CA) | 2004-08-24 | — | — | US | disclosed |
| US-20030187015-A1 | Activated iododerivatives for the treatment of cancer and aids | YATSCOFF RANDALL W (CA) | 2003-10-02 | — | — | US | disclosed |
| US-6511988-B2 | Prevention binding of transcription factor tozinc finger binding compounds | ISOTECHNIKA INC. (CA) | 2003-01-28 | — | — | US | disclosed |
| US-6306871-B1 | IODONITROBENZAMIDE DERIVATIVES AS ANTICARCINOGENIC, ANTITUMOR AGENTS AND VIRICIDES | ISOTECHNIKA INC. (CA) | 2001-10-23 | — | — | US | disclosed |
| US-6225323-B1 | Activated iododerivatives for the treatment of cancer and AIDS | JOSEPH KOZIAK (CA) | 2001-05-01 | — | — | US | disclosed |
| EP-0973727-A2 | ACTIVATED IODODERIVATIVES FOR THE TREATMENT OF CANCER AND AIDS | ISOTECHNIKA,INC. (CA) | 2000-01-26 | — | — | EP | disclosed |
| WO-1998045253-A1 | ACTIVATED IODODERIVATIVES FOR THE TREATMENT OF CANCER AND AIDS | ISOTECHNIKA, INC. (CA) | 1998-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187015-A1 | Activated iododerivatives for the treatment of cancer and aids | IKZF3, ZC3HAV1, ZFP3 | HPGD 2776/4885SMN1; SMN2 4497/4885MEN1 4088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.